Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

Rheumatology

Volumn 50, Issue 1, 2011, Pages 214-221

  Papsdorf, Vera ^a   Horneff, Gerd ^a  

^a Deutsches Kinderrheumazentrum   (Germany)

Author keywords

Corticosteroids; Etanercept; Inactive disease; Juvenile idiopathic arthritis; Methotrexate; Remission; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TRIAMCINOLONE HEXACETONIDE;

ADOLESCENT; ARTICLE; BOY; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE DURATION; DRUG EFFICACY; FEMALE; GIRL; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; POLYARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SCHOOL CHILD; SCORING SYSTEM; SERODIAGNOSIS; SEX DIFFERENCE;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951707346     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq292     Document Type: Article

References (23)

1. Petty RE, Southwood TR, Baum J et al. Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998;25:1991-4.
2. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390-2.
3. Andersson Gare B. Juvenile arthritis-who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 1999;17:367-74.
4. Newacheck PW, Taylor WR. Childhood chronic illness: prevalence, severity, and impact. Am J Public Health 1992;82:364-71.
5. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implication for therapy. N Engl J Med 1990;322:1277-89.
6. Horneff G. Biologika zur Therapie der juvenilen idiopathischen arthritis - update 2007. Akt Rheumatol 2007; 32:1-8.
7. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10: 3049-60.
8. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
9. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
10. Fransen J, Creemers MCW, Van Riel PLCM. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5.
11. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
12. Van der Heijde DMFM, Van't Hof MA, Van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
13. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
14. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
15. Prince FH, Twilt M, ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
16. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 2002;61: 171-3.
17. Mori M, Takei S, Imagawa T et al. Pharmakokinetics, efficacy and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Modern Rheum 2005;15: 397-404.
18. Horneff G, De Bock F, Foeldvari I et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
19. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course rheumatoid arthritis. Arthritis Rheum 2006;6:1987-94.
20. Lovell DJ, Giannini EH, Reiff A et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthrits Rheum 2003;48:218-26.
21. Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009;36: 1078-82.
22. Russo RA, Katsicas MM. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:723-6.
23. Lovell DJ, Giannini EH, Reiff A et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthrits Rheum 2008;58:1496-504.